Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00333502 |
Recruitment Status :
Completed
First Posted : June 5, 2006
Last Update Posted : May 28, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
CRLX101 is a nanopharmaceutical comprised of the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer. CRLX101 is designed to increase the exposure of tumor cells to CPT while minimizing side effects.
OBJECTIVES:
• Determine the safety, toxicity, and the maximum tolerated dose (MTD) of CRLX101 when administered intravenously to subjects with advanced solid tumors.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cancer Solid Tumor | Drug: Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 62 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1b/2a Safety and Pharmacokinetic Study of CRLX101 (Formerly Named IT-101) in the Treatment of Advanced Solid Tumors |
Study Start Date : | May 2006 |
Actual Primary Completion Date : | November 2011 |
Actual Study Completion Date : | April 2012 |

Arm | Intervention/treatment |
---|---|
Experimental: CRLX101 (formerly known as IT-101)
CRLX101 dosing per protocol dose escalation cohorts to MTD, then expansion cohort treated at MTD of CRLX101 15mg/m2
|
Drug: Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
Subjects who meet inclusion/exclusion criteria will receive CRLX101 every other week.
Other Names:
|
- To determine the safety, toxicity and maximum tolerated dose of CRLX101 when administered intravenously to subjects with advanced solid tumors. [ Time Frame: 6 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male and female subjects >18 years of age with advanced, histologically-confirmed solid tumors refractory to standard therapy or for which no standard therapy exists and who have evidence of disease progression documented since their prior therapy.
- Subjects must have measurable or evaluable disease.
- Subjects must not have received prior chemotherapy or radiation for >/= 4 weeks prior to first dose of study drug.
- Subjects may be entered if they have received prior radiation therapy involving </= 30% of the bone marrow. Any prior radiation therapy must have been administered >/= 4 weeks prior to first dose of study drug and the subject must be recovered from the acute toxic effects of the treatment prior to study entry.
- Subjects may be enrolled with a history of treated brain metastases that are clinically stable for >/= 4 weeks prior to first dose of study drug. Subjects may not be currently receiving dexamethasone.
- ECOG performance status of < 2.
- Life expectancy of greater than 12 weeks.
- Subjects must have acceptable organ and marrow function at screening and pre-dose visits.
- Electrocardiogram without evidence of clinically significant conduction abnormalities or active ischemia as determined by the investigator and an acceptable QTc interval.
- The effects of CRLX101 on the developing human fetus are unknown, therefore, women of childbearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Female subjects who are pregnant or nursing.
- Subjects who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to first dose of study drug or those who have not had adverse events return to baseline severity level or a severity level Grade 1 due to agents administered more than 4 weeks prior to first dose of study drug.
- Subjects with a history of congestive heart failure (CHF) requiring medical therapy.
- Subjects with serum amylase or lipase > 1.5X upper limit of normal (ULN).
- Subjects with previous high dose chemotherapy with autologous stem cell rescue bone marrow transplantation.
- Use of any investigational agent or drug within 4 weeks prior to first dose of study drug.
- Metastatic disease to the CNS requiring treatment or radiation therapy.
- Subjects with known untreated brain metastases or treated brain metastases that have not been stable >/= 4 weeks prior to first dose of study drug.
- Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, hypertension, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, as determined by the investigator.
- The presence of active coagulation disorder.
- Subjects with marked baseline prolongation of QT/QTc interval (QTc interval >/= 470 msec for females and QTc interval >/= 450 msec for males).
- Any prior treatment with a topoisomerase I inhibitor.
- Any major surgery </= 4 weeks prior to first dose of study drug.
- Concurrent use of G-CSF or growth factors at the time of initiation of study drug.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00333502
United States, Arizona | |
Virginia G. Piper Cancer Center | |
Scottsdale, Arizona, United States, 85258 | |
United States, California | |
City of Hope National Medical Center | |
Duarte, California, United States, 91010 | |
United States, New Mexico | |
San Juan Oncology Associates | |
Farmington, New Mexico, United States, 87401 |
Principal Investigator: | Yun Yen, M.D., Ph.D. | City of Hope National Medical Center | |
Principal Investigator: | Glenn Weiss, M.D. | Virginia G. Piper Cancer Center | |
Principal Investigator: | Jeffrey D. Neidhart, M.D. | San Juan Oncology Associates |
Responsible Party: | NewLink Genetics Corporation |
ClinicalTrials.gov Identifier: | NCT00333502 |
Other Study ID Numbers: |
CRLX-001 City of Hope IRB number 05127 |
First Posted: | June 5, 2006 Key Record Dates |
Last Update Posted: | May 28, 2020 |
Last Verified: | May 2020 |
Cancer, Neoplasms, Solid Tumor, Ovarian Cancer, Lung Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer, Breast Cancer, Colon Cancer, Endometrial Cancer, |
Kidney (Renal Cell) Cancer, Melanoma, Prostate Cancer, Skin Cancer, Thyroid Cancer, Solid Malignancies |
Neoplasms Camptothecin Antineoplastic Agents, Phytogenic Antineoplastic Agents |
Topoisomerase I Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |